Literature DB >> 8261433

Identification, characterization, and biological activity of somatostatin receptors in human neuroblastoma cell lines.

M Maggi1, E Baldi, G Finetti, F Franceschelli, A Brocchi, R Lanzillotti, M Serio, M G Camboni, C J Thiele.   

Abstract

To investigate the presence of biologically active somatostatin (SS) receptors in neural crest-derived tumors, radioligand binding studies, cyclic AMP accumulation, intracellular calcium, and growth assays were performed in eight human neuroblastoma (NB) cell lines. Mathematical modeling of binding experiments strongly indicates the presence of heterogeneity of sites. The first site (SSR1) is present in 40% of the NB cell lines and binds with low capacity (0.5 pmol/mg protein) and high affinity (0.1-1 nM) SS14, SS28, and analogues. The second site (SSR2) is a high capacity site (200 pmol/mg protein), widely distributed in all of the cell lines investigated, that shows relative selectivity yet low affinity (100 nM) for SS14, SS28, and [D-Trp8]SS14 without any apparent biological activity. SSR1 is coupled to a pertussis toxin-sensitive G protein, inhibits forskolin- or VIP-stimulated adenylate cyclase activity, decreases intracellular free calcium, and mediates inhibition (30%) of both DNA synthesis and cell growth. Analysis of cell cycle distribution in aphidicolin-synchronized SSR1-positive NB cells indicated that this inhibitory effect is partially mediated by a transient accumulation in G0-G1. Our data indicate high affinity binding sites for SS14, and analogues are present and biologically active in a subset of NB cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8261433

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Targeted entry via somatostatin receptors using a novel modified retrovirus glycoprotein that delivers genes at levels comparable to those of wild-type viral glycoproteins.

Authors:  Fang Li; Byoung Y Ryu; Robin L Krueger; Scott A Heldt; Lorraine M Albritton
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

Review 2.  Retinoids and the control of growth/death decisions in human neuroblastoma cell lines.

Authors:  G Melino; C J Thiele; R A Knight; M Piacentini
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

3.  Expressions of Somatostatin Receptor Subtypes (SSTR-1, 2, 3, 4 and 5) in Neuroblastic Tumors; Special Reference to Clinicopathological Correlations with International Neuroblastoma Pathology Classification and Outcomes.

Authors:  Noriko Watanabe; Yoko Nakanishi; Noriko Kinukawa; Sumie Ohni; Yukari Obana; Atsuko Nakazawa; Norimichi Nemoto
Journal:  Acta Histochem Cytochem       Date:  2014-09-12       Impact factor: 1.938

4.  Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models.

Authors:  Libo Zhang; Douglass C Vines; Deborah A Scollard; Trevor McKee; Teesha Komal; Milan Ganguly; Trevor Do; Bing Wu; Natasha Alexander; Reza Vali; Amer Shammas; Travis Besanger; Sylvain Baruchel
Journal:  Contrast Media Mol Imaging       Date:  2017-08-08       Impact factor: 3.161

5.  A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma-LuDO-N.

Authors:  Fredrik Sundquist; Kleopatra Georgantzi; Kirsten Brunsvig Jarvis; Jesper Brok; Minna Koskenvuo; Jelena Rascon; Max van Noesel; Per Grybäck; Joachim Nilsson; Arthur Braat; Mikael Sundin; Sandra Wessman; Nikolas Herold; Lars Hjorth; Per Kogner; Dan Granberg; Mark Gaze; Jakob Stenman
Journal:  Front Pediatr       Date:  2022-03-10       Impact factor: 3.418

6.  Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in Neuroblastoma.

Authors:  Natasha Alexander; Paula Marrano; Paul Thorner; Arlene Naranjo; Collin Van Ryn; Daniel Martinez; Vandana Batra; Libo Zhang; Meredith S Irwin; Sylvain Baruchel
Journal:  J Pediatr Hematol Oncol       Date:  2019-04       Impact factor: 1.289

7.  Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells.

Authors:  Céline Kerros; Thibault Cavey; Brigitte Sola; Philippe Jauzac; Stéphane Allouche
Journal:  J Exp Clin Cancer Res       Date:  2009-06-07

8.  An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with 177Lu-DOTATATE for the treatment of neuroblastoma.

Authors:  Mathias Tesson; Richa Vasan; Andreas Hock; Colin Nixon; Colin Rae; Mark Gaze; Robert Mairs
Journal:  Oncotarget       Date:  2018-06-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.